Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 2/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14635368 | 0.79 | MAOA (0.37) | HTR2CHTR2BMAOBESR1ESR2 | |
| SCHEMBL3832964 | 0.77 | KDM1A (0.37) | KDM1AKDM1BSLC6A2SLC6A3HTR2C | |
| SCHEMBL7019518 | 0.74 | GRM2 (0.36) | — | |
| SCHEMBL23423074 | 0.73 | KMT2A (0.40) | — | |
| SCHEMBL18383187 | 0.73 | POLB (0.43) | KDM1AKDM1BSLC6A2SLC6A3HTR2C | |
| SCHEMBL18383190 | 0.73 | POLB (0.43) | KDM1AKDM1BSLC6A2SLC6A3HTR2C | |
| SCHEMBL1980720 | 0.73 | MAOB (0.41) | KDM1AKDM1BSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1328841 | 0.73 | POLB (0.43) | KDM1AKDM1BSLC6A2SLC6A3HTR2C | |
| SCHEMBL28513561 | 0.72 | HTR2C (0.37) | KDM1AKDM1BSLC6A2SLC6A3HTR2C | |
| Hydrochloric Acid SCHEMBL28513964 | 0.71 | HTR2C (0.39) | KDM1AKDM1BSLC6A2SLC6A3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172334-A1 | TRPV1 ANTAGONISTS | TRPV1, MRGPRX1, MRGPRX4 | KDM1A 2848/4885KDM1B 3644/4885SLC6A2 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.